BLUEBIRD BIO INC (BLUE)

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. The company is headquartered in Somerville, Massachusetts and currently employs 375 full-time employees. The company went IPO on 2013-06-19. The firm is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. The company markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). The company is focused on pursuing curative gene therapies.

Company Info

BLUEBIRD BIO INC

455 Grand Union Boulevard

Somerville MASSACHUSETTS 02142

P: 13394999300

CEO: Nick Leschly

Employees: 375

Website: https://www.bluebirdbio.com/